» Articles » PMID: 18035670

Classification and Grading of Invasive Breast Carcinoma

Overview
Specialty Pathology
Date 2007 Nov 27
PMID 18035670
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

The main reasons for applying a classification system to invasive breast carcinoma are to obtain a correlation with prognosis and tumour biology. Invasive carcinomas may be sub-divided morphologically according to their degree of differentiation. This is achieved in two ways, by assessing histological type and histological grade. A wide range of histological patterns is recognised in invasive carcinoma of the breast and four broad prognostic groups are recognised: the excellent prognosis group comprises tubular, cribriform, mucinous carcinomas; the good group tubular mixed, mixed ductal NST/special type and classical lobular carcinoma; the average group mixed lobular, medullary and atypical medullary carcinoma and the poor group is composed of ductal NST, mixed ductal and solid lobular carcinoma understanding of the biology of breast cancer. For example, tumours with a medullary phenotype which express basal cytokeratins and are p53 positive and ER and c-erbB-2 negative are strongly predictive of the BRCA-1 gene-mutation carrier state. Histological grading refers to the semi-quantitative evaluation of the morphological structure of breast carcinomas. In the Nottingham method three characteristics of the tumour are evaluated, glandular differentiation, nuclear pleomorphism and mitotic counts. A numerical scoring system on a scale of 1-3 is used to ensure that each factor is assessed individually. Overall grade is assigned as follows: Grade 1: 3-5 points, Grade 2: 6-7 points, Grade 3: 8-9 points. There is a highly significant relationship between histological grade and prognosis; survival worsens with increasing grade. Histological grading has been shown to have good reproducibility and has been adopted for use in Europe, Australasia and the United States. When combined with pathological tumour size and lymph node stage into the Nottingham Prognostic Index there is excellent stratification for patient management.

Citing Articles

Failure to progress: breast and prostate cancer cell lines in developing targeted therapies.

James C, Whitehead A, Plummer J, Thompson R, Badal S Cancer Metastasis Rev. 2024; 43(4):1529-1548.

PMID: 39060878 DOI: 10.1007/s10555-024-10202-w.


Canine Mammary Tumors as a Potential Model for Human Breast Cancer in Comparative Oncology.

Razavirad A, Rismanchi S, Mortazavi P, Muhammadnejad A Vet Med Int. 2024; 2024:9319651.

PMID: 38766503 PMC: 11101259. DOI: 10.1155/2024/9319651.


Dynamic contrast-enhanced magnetic resonance imaging features and apparent diffusion coefficient value of HER2-positive/HR-negative breast carcinoma.

Chen P, Zhao S, Guo W, Shao G Quant Imaging Med Surg. 2023; 13(8):4816-4825.

PMID: 37581065 PMC: 10423352. DOI: 10.21037/qims-22-1318.


Concordance between core needle biopsy and surgical excision for breast cancer tumor grade and biomarkers.

Shanmugalingam A, Hitos K, Hegde S, Al-Mashat A, Pathmanathan N, Edirimmane S Breast Cancer Res Treat. 2022; 193(1):151-159.

PMID: 35229238 DOI: 10.1007/s10549-022-06548-w.


A population-based comparison of treatment, resource utilization, and costs by cancer stage for Ontario patients with HER2-positive breast cancer.

Brezden-Masley C, Fathers K, Coombes M, Pourmirza B, Xue C, Jerzak K Breast Cancer Res Treat. 2020; 185(3):807-815.

PMID: 33090268 PMC: 7921035. DOI: 10.1007/s10549-020-05976-w.